P846: EXPRESSION SIGNATURE OF TP53 BIALLELIC INACTIVATION IDENTIFIES A GROUP OF MULTIPLE MYELOMA PATIENTS WITHOUT THIS GENETIC CONDITION BUT WITH DISMAL OUTCOME.

por De Ramón, C., Rojas, E. A., Cardona-Benavides, I. J., Mateos, M. V., Corchete, L. A., Gutiérrez, N. C.
Publicado 2022

From Waldenström’s macroglobulinemia to aggressive diffuse large B-cell lymphoma: a whole-exome analysis of abnormalities leading to transformation

por Jiménez, C, Alonso-Álvarez, S, Alcoceba, M, Ordóñez, G R, García-Álvarez, M, Prieto-Conde, M I, Chillón, M C, Balanzategui, A, Corral, R, Marín, L A, Gutiérrez, N C, Puig, N, Sarasquete, M E, González, M, García-Sanz, R
Publicado 2017

P848: TINOSTAMUSTINE (EDO-S101), AN ALKYLATOR AND HISTONE DEACETYLASE INHIBITOR, ENHANCES THE EFFICACY OF DARATUMUMAB IN PRECLINICAL MODELS OF MULTIPLE MYELOMA

por Diaz-Tejedor, A., San-Segundo, L., Corchete, L. A., González-Méndez, L., Martín-Sánchez, M., Lorenzo-Mohamed, M., González-Rodríguez, M., Cruz-Hernández, M., Sánchez-Blázquez, M., Gutiérrez, N. C., Mateos, M.-V., Garayoa, M., Ocio, E. M., Paíno, T.
Publicado 2022